BRIDGEWATER, N.J., May 29 Ortho Biotech today announcedthat two clinical studies for DOXIL(R) (doxorubicin HCl pegylated liposomeinjection) will be presented at the 44th American Society of Clinical Oncology(ASCO) Annual Meeting at McCormick Place in Chicago from May 30 to June 3,2008.
"We are pleased that ASCO has accepted these data for presentation at theannual meeting," said Craig Tendler, M.D., Vice President, Medical Affairs,Oncology/Nephrology, Ortho Biotech Products, L.P. "Through our ongoinginvestigation of DOXIL, Ortho Biotech is committed to oncology clinicalresearch and helping patients fight cancer."
DOXIL is indicated in combination with VELCADE(R) (bortezomib) for thetreatment of patients with multiple myeloma who have not previously receivedVELCADE and have received at least one prior therapy, and for the treatment ofpatients with ovarian cancer whose disease has progressed or recurred afterprior platinum based therapy.
IMPORTANT SAFETY INFORMATION
Cardiotoxicity, infusion reaction, myelosuppression, liver impairment,Substitution
DOXIL is marketed in the United States by Ortho Biotech Products, L.P.,and in Israel by Janssen-Cilag. Schering-Plough Corporation, under alicensing agreement, has exclusive rights to market the medication as CAELYXthroughout the rest of the world, excluding Japan and Israel. For moreinformation about DOXIL, please visit www.DOXIL.com.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical companydevoted to helping improve the lives of patients with cancer and with anemiadue to multiple causes, including chronic kidney disease. Since it wasfounded in 1990, Ortho Biotech and its worldwide affiliates have earned aglobal reputation for researching, manufacturing and marketing innovativeproducts that enhance patients' health. Located in Bridgewater, N.J., OrthoBiotech is an established market leader in Epoetin alfa therapy for anemiamanagement. The company also markets treatments for recurrent ovarian cancer,rejection of transplanted organs and other serious illnesses. For moreinformation, visit www.orthobiotech.com.
NOTE: This release corresponds to ASCO abstracts 8562 and 8563 andpublication number 20505.Data from the following studies will be presented: -- The Effect of Pegylated Liposomal Doxorubicin Plus Bortezomib in Multiple Myeloma Patients with Renal Insufficiency (Abstract 8562) Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General Poster Session: Lymphoma and Plasma Cell Disorders, S Hall A1, Poster 47A Authors: J. Blade, P. Sonneveld, J. San Miguel, H. Sutherland, R. Hajek, A. Nagler, A. Spencer, T. Robak, J. L. Harousseau, R. Z. Orlowski, The DOXIL-MMY-3001 Study Investigators -- Phase II Trial of Pegylated Liposomal Doxorubicin (PLD), Rituxan, Cyclophosphamide, Vincristine, and Prednisone in Aggressive B-Cell Non-Hodgkin's Lymphoma (Abstract 8563) Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General Poster Session: Lymphoma and Plasma Cell Disorders, S Hall A1, Poster 47B Authors: H. Gu, A. Tulpule, N. Berman, C. Duran, S. G. Groshen, L. Buchanan, W. Boswell, B. Nathwani, A. M. Levine In addition, the following study was accepted for publication: -- Activity and Toxicity of Pegylated Liposomal Doxorubicin in Combination Regimen (DRCOP) for Patients >60 Years Old With Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Phase II Study (Abstract 20505) Publication only Authors: M. A. Rodriguez, M. Fanale, F. B. Hagemeister, P. McLaughlin, B. Pro, J. E. Romaguera, L. Kwak, L. E. Fayad, J. Durand
SOURCE Ortho Biotech